ReviewJournal of cardiovascular translational research2010
Protein therapeutics for cardiac regeneration after myocardial infarction.
Review in Journal of cardiovascular translational research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 118 citations in OpenAlex.
- A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction.Materials today. Bio · 2026Article
- Targeted drug delivery systems for cardiovascular disease treatment: principles, targeting strategies, and future prospects.Annals of medicine · 2026Review
- Multimodal characterization of sustained bioagent release from an epicardial depot for long-term biomaterial incorporation.Biomaterials · 2026Article
- A 3D Bioprinted dECM/CSCA/SA/NC Hybrid Scaffold for Myocardial Infarction Healing.Applied biochemistry and biotechnology · 2026Article
- Customized Heparinized Alginate and Collagen Hydrogels for Tunable, Local Delivery of Angiogenic Proteins.ACS biomaterials science & engineering · 2025Article
- Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma.International journal of molecular sciences · 2024Article
- The Current State of Extracellular Matrix Therapy for Ischemic Heart Disease.Medical sciences (Basel, Switzerland) · 2024Review
- Therapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease.iScience · 2023Review
- Supramolecular Phenylalanine-Derived Hydrogels for the Sustained Release of Functional Proteins.ACS biomaterials science & engineering · 2023Article
- An injectable conductive hydrogel restores electrical transmission at myocardial infarct site to preserve cardiac function and enhance repair.Bioactive materials · 2023Article
- Positive effect of Periostin on repair of Isopreternol induced ischemic damaged cardiomyocyte: an in vitro model.Regenerative therapy · 2022Article
- Hyaluronan and elastin-like protein (HELP) gels significantly improve microsphere retention in the myocardium.Biomaterials science · 2022Article
- Signaling pathways and targeted therapy for myocardial infarction.Signal transduction and targeted therapy · 2022Review
- GDF15 and Cardiac Cells: Current Concepts and New Insights.International journal of molecular sciences · 2021Review
- Myocardial protection by heparin-based coacervate of FGF10.Bioactive materials · 2021Article
- Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel.Pharmaceutics · 2021Article
- Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease.Frontiers in immunology · 2021Review
- Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Effect of a dianthin G analogue in the differentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes.Molecular and cellular biochemistry · 2020Article
- Spatiotemporal delivery of basic fibroblast growth factor to directly and simultaneously attenuate cardiac fibrosis and promote cardiac tissue vascularization following myocardial infarction.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although most medicines have historically been small molecules, many newly approved drugs are derived from proteins. Protein therapies have been developed for treatment of diseases in almost every organ system, including the heart. Great excitement has now arisen in the field of regenerative medicine, particularly for cardiac regeneration after myocardial infarction. Every year, millions of people suffer from acute myocardial infarction, but the adult mammalian myocardium has limited regeneration potential. Regeneration of the heart after myocardium infarction is therefore an exciting target for protein therapeutics. In this review, we discuss different classes of proteins that have therapeutic potential to regenerate the heart after myocardial infarction. Protein candidates have been described that induce angiogenesis, including fibroblast growth factors and vascular endothelial growth factors, although thus far clinical development has been disappointing. Chemotactic factors that attract stem cells, e.g., hepatocyte growth factor and stromal cell-derived factor-1, may also be useful. Finally, neuregulins and periostin are proteins that induce cell-cycle reentry of cardiomyocytes, and growth factors like IGF-1 can induce growth and differentiation of stem cells. As our knowledge of the biology of regenerative processes and the role of specific proteins in these processes increases, the use of proteins as regenerative drugs could develop as a cardiac therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.